Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00058539
Status:
COMPLETED
Last Update Posted:
2015-06-23
First Post:
2003-04-08
Brief Title:
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Open-Label Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Omnitarg Pertuzumab in Subjects With Castration-Resistant Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate safety and efficacy of Omnitarg Pertuzumab on cancerous lesions in men with castration-resistant hormone-refractory prostate cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None